Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

Combination of abiraterone and cabazitaxel in metastatic castration-resistant...

Dr Joaquin Mateo - Institute of Cancer Research, London, UK

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer ( Dr Joaquin Mateo - Institute of Cancer Research, London, UK )

Is there a role for androgen deprivation therapy combined with radiotherapy in...

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada

Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer? ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )

Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial...

Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA

Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer ( Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA )

New approach to prostate cancer screening

Dr Sanoj Punnen - University of Miami, Miami, USA

New approach to prostate cancer screening ( Dr Sanoj Punnen - University of Miami, Miami, USA )

ASCO GU 2015: Prostate highlights from day one

Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin

ASCO GU 2015: Prostate highlights from day one ( Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin )

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Prof Thomas Powles - Barts Health, London, UK

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer ( Prof Thomas Powles - Barts Health, London, UK )

Metastatic prostate cancer - Interpreting negative trial results

Prof Stephane Oudard and Prof Noel Clarke

Metastatic prostate cancer - Interpreting negative trial results ( Prof Stephane Oudard and Prof Noel Clarke )

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma:...

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Are we doing all we can to manage adverse events?

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

mRCC: Are we doing all we can to manage adverse events? ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Real-world experience: achieving efficacy beyond clinical trials

Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA

mRCC: Real-world experience: achieving efficacy beyond clinical trials ( Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA )

mRCC: Understanding the patient's perspective

Dr David Cella - Northwestern University, Chicago, USA

mRCC: Understanding the patient's perspective ( Dr David Cella - Northwestern University, Chicago, USA )

mRCC: Panel discussion

Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella

mRCC: Panel discussion ( Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella )

More from ecancer